Evidence map›Paper›PMID 41870675›Full record

ReviewHeart failure reviews2026

ANSWER-HF: sacubitril-valsartan reduces NT-proBNP in heart failure due to Chagas cardiomyopathy despite no reverse remodeling.

Eduardo Bello Martins, Vagner Madrini, Paulo Vinicius Ramos Souza, Caio de A M Tavares, Monica T Albuquerque, Karla Espirito Santo, Josephine A Harrington, Mario Enrico Canonico, Abdelghani El Rafei, Marc P Bonaca and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Eduardo Bello MartinsHospital Israelita Albert Einstein, Av. Albert Einstein 627, São Paulo, SP, 05620-900, Brazil.
Vagner MadriniHospital Israelita Albert Einstein, Av. Albert Einstein 627, São Paulo, SP, 05620-900, Brazil.
Paulo Vinicius Ramos SouzaInstituto do Coracao (InCor), Faculdade de Medicina, Hospital das Clinicas HCFMUSP, Universidade de São Paulo, São Paulo, Brazil.
Caio de A M TavaresHospital Israelita Albert Einstein, Av. Albert Einstein 627, São Paulo, SP, 05620-900, Brazil.
Monica T AlbuquerqueHospital Israelita Albert Einstein, Av. Albert Einstein 627, São Paulo, SP, 05620-900, Brazil.
Karla Espirito SantoHospital Israelita Albert Einstein, Av. Albert Einstein 627, São Paulo, SP, 05620-900, Brazil.
Josephine A HarringtonColorado Prevention Center, Aurora, CO, USA.
Mario Enrico CanonicoColorado Prevention Center, Aurora, CO, USA.
Abdelghani El RafeiColorado Prevention Center, Aurora, CO, USA.
Marc P BonacaColorado Prevention Center, Aurora, CO, USA.
Patricia O GuimaraesHospital Israelita Albert Einstein, Av. Albert Einstein 627, São Paulo, SP, 05620-900, Brazil. patricia.oguimaraes@einstein.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic Chagas cardiomyopathy (CCC) is one of the leading causes of heart failure with reduced ejection fraction (HFrEF) in Latin America, yet robust evidence for optimal medical therapy remains scarce. This mini-review examines the results, strengths and limitations of the ANSWER-HF study, a single-center, double-blind randomized clinical trial comparing sacubitril–valsartan with enalapril in 190 patients with CCC-HFrEF over six months. The primary endpoint was change in left ventricular ejection fraction (LVEF). Secondary endpoints included N-terminal pro-B-type natriuretic peptides, echocardiography and functional parameters, clinical events and safety assessments. No significant differences were observed in LVEF, cardiac remodeling, 6-minute walk distance or clinical outcomes between study groups. However, patients randomized to sacubitril–valsartan achieved a significantly greater reduction in NT-proBNP at 6 months. These findings highlight the biological effect of sacubitril-valsartan in this population but reinforces the need for larger, long-term studies, powered to hard clinical endpoints, to further establish the role of sacubitril-valsartan in CCC.

Indexed as

AminobutyratesChagas CardiomyopathyHeart FailureNatriuretic Peptide, BrainPeptide FragmentsTetrazolesVentricular RemodelingAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationsHumansRandomized Controlled Trials as TopicStroke VolumeTreatment OutcomeValsartanVentricular Function, LeftAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationsNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)sacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanChagas' cardiomyopathyEnalaprilHeart failureSacubitril-valsartan

Identifiers

PMID41870675

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.